10x Genomics (NASDAQ:TXG) (NASDAQ: TXG) is a life sciences technology company specializing in high-resolution genomic analysis. Since its founding in 2012 and headquartered in Pleasanton, California, the company has developed proprietary platforms that enable researchers to study biological systems at single-cell and spatial resolution. By integrating microfluidics, molecular barcoding and advanced bioinformatics, 10x Genomics provides tools that help scientists uncover cellular heterogeneity and molecular interactions across diverse tissue types.
The company’s flagship Chromium platform supports single-cell RNA sequencing, single-cell immune profiling and single-cell assay for transposase-accessible chromatin (scATAC-seq). In addition to the Chromium system, 10x Genomics offers the Visium Spatial Gene Expression solution, which allows researchers to map gene activity within tissue sections. These products are complemented by software pipelines and analytical tools that facilitate data processing, visualization and interpretation, making complex genomic data accessible to both academic and industrial researchers.
10x Genomics serves a global customer base that spans academic institutions, biotechnology firms, pharmaceutical companies and government research laboratories. Its instruments and reagents are distributed through direct sales teams in North America, Europe and parts of Asia, with additional collaborations and distribution partners extending its reach to emerging markets. The company also invests in customer support and training programs, hosting workshops and webinars to help users adopt and optimize its technologies for diverse research applications.
Under the leadership of co-founder and Chief Executive Officer Serge Saxonov, 10x Genomics has expanded its product portfolio and scaled its operations to meet growing demand for single-cell and spatial analysis. Saxonov, who co-founded the company after a career in software engineering, has guided 10x Genomics through multiple product launches and its initial public offering. The executive team’s focus on innovation and strategic partnerships continues to drive the company’s mission to transform biological research and accelerate discoveries in health and disease.
